HOME CONTACT ABOUT PRODUCT PIPELINE RESOURCES PARTNERING INVESTORS MEDIA CAREERS For over 25 years, Acadia has been trailblazing breakthroughs for people with neurological conditions. The Acadia family continues to fulfill the promise of science to deliver vital solutions to people who need them most to help enable brighter moments to shine through for patients & their loved ones. We invite you to learn more about our history. 2020 Acadia and Neuren Pharmaceuticals announce rare pediatric disease designation for trofinetide for the treatment of Rett syndrome* 2019 Acadia initiates Phase 3 CLARITY program with pimavanserin as adjunctive treatment for major depressive disorder and completes enrollment in ENHANCE and ADVANCE schizophrenia trials. 2018 Acadia adds trofinetide to CNS pipeline and reports positive Phase 2 CLARITY results for pimavanserin as adjunctive treatment for major depressive disorder.* 2017 FDA grants Breakthrough Therapy Designation to pimavanserin for dementia-related psychosis.* 2016 FDA approves NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia announces positive results in Alzheimer's disease psychosis and initiates studies with pimavanserin for major depressive disorder and schizophrenia. 2015 Acadia submits NUPLAZID® (pimavanserin) New Drug Application for Parkinson’s disease psychosis to the U.S. FDA and is granted Priority Review. 2014 Acadia receives FDA Breakthrough Therapy Designation for NUPLAZID® (pimavanserin) for Parkinson's disease psychosis. 2013 Phase 3 data for pimavanserin in patients with Parkinson’s disease psychosis presented at the American Academy of Neurology and published in The Lancet. 2012 Acadia reports positive Phase 3 data for pimavanserin in patients with Parkinson’s disease psychosis. 2010 Acadia initiates Phase 3 study in Parkinson’s disease psychosis. 2009 Acadia forms collaboration with Biovail to develop and commercialize pimavanserin in North America. 2007 Acadia reports positive Phase 2 data for pimavanserin as a co-therapy for patients with schizophrenia. 2006 Acadia reports positive Phase 2 data for pimavanserin in patients with Parkinson’s disease psychosis. 2004 Acadia completes its initial public offering and trades under the symbol “ACAD” on the NASDAQ Stock Market. 2001 Pimavanserin first synthesized by an Acadia chemist. 1999 Acadia scientists start a project aimed at discovering 5-HT2A inverse agonists. 1997 Company changes its name to Acadia Pharmaceuticals Inc. and moves headquarters to San Diego. 1993 Receptor Technologies is founded by Mark Brann, Ph.D., a professor at the University of Vermont. *Information presented above is related to an investigational use of NUPLAZID (pimavanserin) or an investigational agent. Safety and efficacy of these targeted indications or an investigation agent has not been established or approved by the FDA. Please read the full Prescribing Information for FDA approved indication for NUPLAZID, including Boxed WARNING. ABOUT MANAGEMENT TEAM BOARD OF DIRECTORS OUR PURPOSE, MISSION & VALUES HISTORY Print page Share PRIVACY COOKIES PRIVACY SHIELD TERMS EMAIL © 2021 Acadia Pharmaceuticals Inc. Acadia and NUPLAZID are registered trademarks of Acadia Pharmaceuticals Inc. All rights reserved. By using this website without changing your cookie settings in your browser, you agree to our use of cookies. For further details on cookies, how we use cookies and how to delete or block the use of cookies, please read our .